When Disclosure Falls Behind the Court Docket: the Patent Case of Creality (03388.HK)
*By Alex Rivera, Unicorn Analytics*
For Hong Kong investors, the central question raised by a U.S. patent litigation of the Hong Kong-listed Shenzhen Creality 3D Technology Co Ltd (03388.HK) is not who will ultimately prevail at trial. It is whether the company has given the market sufficiently specific, accurate and timely information as the case has evolved.
Creality listed on the Stock Exchange of Hong Kong in May 2026. In its IPO prospectus it described a U.S. patent dispute involving certain 3D-scanning patents and products, noted a mixed summary-judgment outcome, and concluded that any potential liability was immaterial. It pointed to limited recent sales of the accused scanners, the cessation of those products, a supplier indemnity and legal advice.
The prospectus did not name the plaintiff, Artec Europe, or the case number, and it incorrectly referred to the forum as a New York State court rather than the federal court in the Eastern District of New York.
After public questions during the offering period, Creality issued a clarification in early June restating that the matter had already been disclosed and would not have a material adverse effect. Its subsequent interim results continued to treat the litigation as immaterial and reported no material subsequent events after 30 June, even though a significant court ruling had intervened in July.
That July ruling is the most consequential recent development. On 23 July the U.S. court excluded Creality’s damages expert, finding his reasonable-royalty analysis fundamentally flawed because it relied on a non-arm’s-length cooperation agreement between the defendants that was neither a patent licence nor a proper benchmark. At the same time the court allowed Artec’s damages expert to testify. The practical effect is an asymmetry: Artec retains expert support for its damages case while Creality cannot rely on the excluded analysis.
The procedural posture of the patents themselves also requires precise description. In April 2026 the court granted Creality summary judgment of no literal infringement on one of the three patents. It did not, however, remove that patent from the case. The court directed that claims under all three patents proceed to trial: literal infringement claims on two patents and, to the extent asserted, infringement under the doctrine of equivalents on the third.
Creality later moved to strike the doctrine-of-equivalents theory and the willfulness allegations that can support enhanced damages. Those motions remain pending. Artec has opposed the doctrine-of-equivalents motion and was due to respond on willfulness. None of these applications has been granted, and the issues are expected to be tried.
Against this background, Creality’s materiality assessment rests heavily on two pillars: the disclosed sales figures and the advice of counsel. Both invite scrutiny.
The sales numbers cited in the prospectus cover 2023 to 2025, a period after successor products had begun to replace the accused models. They therefore capture the tail of the products’ commercial life rather than the years when those models were the primary offerings. Early litigation records also show substantial crowdfunding activity for one of the products before a court-ordered freeze. In addition, Creality faces potential joint and several liability with its co-defendant, and the question of willfulness remains live. These factors suggest that the disclosed recent sales figures alone may not fully capture the scale of possible exposure.
The counsel pillar has also shifted. The July ruling removed the defendants’ damages expert from the case. New counsel appeared for Creality and its co-defendant in August. Assessments prepared under the previous representation, particularly those that rested in part on the now-excluded expert analysis, at least warrant fresh evaluation. Creality has not issued a further voluntary announcement addressing the July order.
Materiality is not frozen on the date a prospectus is signed. Low recent sales of specific products are a relevant quantitative input, but they are not the only one. When claims under all three patents remain headed for trial, when the damages-expert field has become asymmetric, and when potential remedies include royalties, enhanced damages or injunctive relief, qualitative factors also matter: the strategic importance of the technology, reputational effects, management attention, the strength of any indemnity, and the company’s broader intellectual-property position.
None of this predicts the outcome of the January 2027 trial or establishes that the litigation will prove financially material. Creality continues to contest liability and the scope of the claims. The court has not found infringement. Yet the record shows a case that has continued to develop after the prospectus and the June clarification.
For a newly listed company that emphasises innovation in scanning and related ecosystems, the gap between a risk mentioned in a long document and a risk explained with sufficient specificity and currency is a legitimate subject for investor attention.
Clear disclosure is the mechanism through which markets assess and price risk. When court developments alter the picture, the information available to investors should keep pace.